MS
McCarthy Sean A.
首席执行官
C-suiteM
内部人交易记录
首席执行官尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by McCarthy Sean A., 首席执行官. Officer active across 1 company, notably CytomX Therapeutics, Inc.. Aggregated, 23 filings have been recorded. Breakdown: 0 buy · 7 sells. Total volume traded: €1.7m. History available since 30 September 2019. The latest transaction was disclosed on 17 March 2026 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to McCarthy Sean A.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报23 总计
118,969 股@ US$6.42339.7% 占其流量Common StockSEC:0001610717-26-000124:0
210,000 股0Common StockSEC:0001610717-26-000039:0
101,793 股@ US$4.537719.4% 占其流量Class A Common StockSEC:0001610717-25-000372:0
150,000 股0Common StockSEC:0001610717-25-000234:0
37,656 股@ US$0.5991.2% 占其流量Common StockSEC:0001610717-25-000086:0
180,000 股0Common StockSEC:0001610717-25-000016:0
37,500 股0Common StockSEC:0001610717-24-000432:0
109,768 股@ US$1.57499.5% 占其流量Common StockSEC:0001610717-24-000190:0
20,223 股@ US$2.08552.3% 占其流量Common StockSEC:0001610717-24-000178:0
90,000 股0Common StockSEC:0001610717-24-000036:0
13,551 股@ US$1.38071.0% 占其流量Common StockSEC:0001610717-23-000423:0
37,500 股0Common StockSEC:0001610717-23-000411:0
40,000 股0Common StockSEC:0001610717-23-000297:0
16,535 股@ US$1.57491.4% 占其流量Common StockSEC:0001610717-23-000061:0
7,121 股@ US$1.88050.8% 占其流量Common StockSEC:0001140361-23-012618:0
105,000 股0Common StockSEC:0001567619-23-001930:0
40,000 股0Common StockSEC:0001567619-22-014299:0
66,742 股@ US$0.9450.0082% mcap4.2% 占其流量Common StockSEC:0001567619-22-010091:0
75,000 股0Common StockSEC:0001567619-22-002521:0
92,113 股@ US$1.13394.3% 占其流量Common StockSEC:0001567619-21-015554:0
100,000 股@ US$7.044728.3% 占其流量Common StockSEC:0001567619-21-012419:0
30 股@ US$1.13390.0% 占其流量Common StockSEC:0001567619-21-012252:0
4,500 股0Common StockSEC:0001567619-21-011808:0
About McCarthy Sean A.
Sean A. McCarthy is President and Chief Executive Officer at CytomX Therapeutics, Inc. He has filed 23 disclosures in total, and across the sampled recent filings from 2021-06-08 to 2026-03-19, sales total EUR 1742673 and the most frequent transaction nature is Option exercise.